Literature DB >> 88514

5-Azacytidine hydrolysis kinetics measured by high-pressure liquid chromatography and 13C-NMR spectroscopy.

K K Chan, D D Giannini, J A Staroscik, W Sadee.   

Abstract

Hydrolysis of 5-azacytidine, an experimental anticancer drug, in aqueous buffers was measured using a high-pressure liquid chromatographic (HPLC) procedure and a 13C-NMR method. The former utilized a 17.5-micron Aminex A-6 strong cation-exchanger column eluted with 0.4 M, pH 4.6 ammonium formate buffer at a flow rate of 0.4 ml/min. The hydrolysis sequence as well as the existence of a labile intermediate, N-formylguanylribosylurea, was unequivocally established using 6-13C-5-azacytidine and NMR spectral techniques. A reversible ring opening step to the N-formylguanylribosylurea with an equilibrium constant of 0.58 +/- 0.03 between pH 5.6 and 8.5, followed by an irreversible formation of guanylribosylurea, was found by HPLC. The data confirm previous assumptions on the hydrolytic kinetics. The pH dependency of hydrolysis was examined, and the hydrolysis profile gave a normal V shape with the most stable pH at 7.0. Rather stable intravenous dosage forms can be formulated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 88514     DOI: 10.1002/jps.2600680705

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  5,6-Dihydro-5-aza-2'-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors.

Authors:  Jonathan M Rawson; Richard H Heineman; Lauren B Beach; Jessica L Martin; Erica K Schnettler; Michael J Dapp; Steven E Patterson; Louis M Mansky
Journal:  Bioorg Med Chem       Date:  2013-08-20       Impact factor: 3.641

2.  DNA demethylation induced by 5-azacytidine does not affect fragile X expression.

Authors:  T W Glover; J Coyle-Morris; L Pearce-Birge; C Berger; R M Gemmill
Journal:  Am J Hum Genet       Date:  1986-03       Impact factor: 11.025

3.  Enhanced in Vitro Anti-Tumor Activity of 5-Azacytidine by Entrapment into Solid Lipid Nanoparticles.

Authors:  Farhad Jahanfar; Akbar Hasani; Dariush Shanebandi; Mohammad Rahmati; Hamed Hamishehkar
Journal:  Adv Pharm Bull       Date:  2016-09-25

4.  RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.

Authors:  Josephine Aimiuwu; Hongyan Wang; Ping Chen; Zhiliang Xie; Jiang Wang; Shujun Liu; Rebecca Klisovic; Alice Mims; William Blum; Guido Marcucci; Kenneth K Chan
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

5.  Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice.

Authors:  J Quddus; K J Johnson; J Gavalchin; E P Amento; C E Chrisp; R L Yung; B C Richardson
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Chemical decomposition of 5-aza-2'-deoxycytidine (Decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry.

Authors:  Daniel K Rogstad; Jason L Herring; Jacob A Theruvathu; Artur Burdzy; Christopher C Perry; Jonathan W Neidigh; Lawrence C Sowers
Journal:  Chem Res Toxicol       Date:  2009-06       Impact factor: 3.739

7.  Pharmacokinetics of 5,6-dihydro-5-azacytidine (NSC-264880) in the foxhound.

Authors:  L Malspeis; H Cheng; A E Staubus
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

8.  Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine.

Authors:  Amy Ziemba; Eugene Hayes; Burgess B Freeman; Tao Ye; Giuseppe Pizzorno
Journal:  Chemother Res Pract       Date:  2011-12-18

9.  2'-Deoxyriboguanylurea, the primary breakdown product of 5-aza-2'-deoxyribocytidine, is a mutagen, an epimutagen, an inhibitor of DNA methyltransferases and an inducer of 5-azacytidine-type fragile sites.

Authors:  Katarzyna Lamparska; Jarrod Clark; Gail Babilonia; Victoria Bedell; Wesley Yip; Steven S Smith
Journal:  Nucleic Acids Res       Date:  2012-07-31       Impact factor: 16.971

10.  AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo.

Authors:  A Unnikrishnan; A N Q Vo; R Pickford; M J Raftery; A C Nunez; A Verma; L B Hesson; J E Pimanda
Journal:  Leukemia       Date:  2017-11-29       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.